Lena Marie Spindler

Scientist Formulation Development Boehringer Ingelheim

Lena Marie Spindler, Ph.D., is a Scientist in Pharmaceutical Development Biologicals, specializing in advancing biologic drug formulations and delivery systems. With a strong background in biochemistry and pharmaceutical sciences, Lena focuses on optimizing therapeutic protein stability, efficacy, and manufacturability. She plays a key role in developing innovative solutions that enhance biologic therapies’ safety and patient outcomes. Lena holds a Ph.D. in Biomaterials and Nanotechnology and has contributed to several international projects bridging research and development in biologics. Passionate about scientific innovation, she is dedicated to improving pharmaceutical development through cutting-edge research and collaboration.

Seminars

Thursday 29th January 2026
Panel Discussion: Overcoming Challenges of Injectable Depots & the Eye’s Immune Environment with Hydrogels, Polymers, & Port Delivery Systems
11:45 am
  • Use of natural hydrogels that shear thin during injection and then gel in situ, breaking down into natural amino acids to avoid immune reactions and ensure safety in retinal cells and animal models
  • Comparison of implantable depots that are refillable or biodegradable, focusing on the importance of optically transparent, minimally invasive systems that do not impact visual fields or intraocular pressure
  • Review of clinical concerns such as depot migration, inflammation, and the impact on retinal neurons, highlighting how new materials can reduce risks compared to traditional PLGA or synthetic hydrogels
  • Discussion of innovative port delivery systems that slowly release proteins over extended periods while using familiar injection techniques, potentially reducing injection frequency and improving patient adherence
Wednesday 28th January 2026
Matching Formulation to Delivery Method: Optimizing Biocompatibility, Release Kinetics, & Clinical Outcomes
5:00 pm
  •  The importance of matching drug formulation specifically to the delivery route rather than using a one-size-fits-all approach, ensuring compatibility with intravitreal versus other ocular delivery methods
  • Challenges in maintaining drug stability and bioactivity, especially for sensitive biologics and antibodies, without modifying the drug, preserving its therapeutic effect over time
  • Addressing immune response concerns in the eye where materials must be biocompatible, minimizing inflammation near delicate retinal neurons to avoid vision deterioration
  • Strategies to optimize release duration and dose by tuning formulations, including sustained release over months using adaptable gels and hydrogels that can be delivered with small gauge needles
Lena Marie Spindler, Scientist Formulation Development, Boehringer Ingelheim
View all Speakers
View Event Brochure